1. Matrix metalloproteinases and risk stratification in patients undergoing surgical revascularisation for critical limb ischaemia
- Author
-
Lucia Butrico, Raffaele Grande, Mafalda Massara, Raffaele Serra, Giovanni De Caridi, Francesco Fugetto, Roberta Stefanelli, Sebastiano Gangemi, Francesco Spinelli, Antonio David, Manuela Colosimo, and Stefano de Franciscis
- Subjects
Male ,medicine.medical_specialty ,medicine.medical_treatment ,Dermatology ,Disease ,030204 cardiovascular system & hematology ,Matrix metalloproteinase ,peripheral artery disease ,Amputation, Surgical ,030207 dermatology & venereal diseases ,03 medical and health sciences ,0302 clinical medicine ,Ischemia ,amputation ,medicine ,Humans ,In patient ,Aged ,Aged, 80 and over ,Foot gangrene ,business.industry ,Critical limb ischaemia ,foot gangrene ,revascularisation ,Original Articles ,matrix metalloproteinases ,Matrix Metalloproteinases ,Surgery ,body regions ,Treatment Outcome ,Amputation ,Lower Extremity ,Risk stratification ,Female ,business ,Vascular Surgical Procedures ,Major amputation - Abstract
Critical limb ischaemia (CLI) is the most advanced form of peripheral artery disease (PAD) and it is often associated with foot gangrene, which may lead to major amputation of lower limbs, and also with a higher risk of death due to fatal cardiovascular events. Matrix metalloproteinases (MMPs) seem to be involved in atherosclerosis, PAD and CLI. Aim of this study was to evaluate variations in MMP serum levels in patients affected by CLI, before and after lower limb surgical revascularisation through prosthetic or venous bypass. A total of 29 patients (7 females and 22 males, mean age 73·4 years, range 65-83 years) suffering from CLI and submitted to lower extremity bypass (LEB) in our Institution were recruited. Seven patients (group I) underwent LEB using synthetic polytetrafluoroethylene (PTFE) graft material and 22 patients (group II) underwent LEB using autogenous veins. Moreover, 30 healthy age-sex-matched subjects were also enrolled as controls (group III). We documented significantly higher serum MMPs levels (P < 0·01) in patients with CLI (groups I and II) with respect to control group (group III). Finally, five patients with CLI (17·2%) showed poor outcomes (major amputations or death), and enzyme-linked immunosorbent assay (ELISA) test showed very high levels of MMP-1 and MMP-8. MMP serum levels seem to be able to predict the clinical outcomes of patients with CLI.
- Published
- 2015